Maryland Becomes 5th State to Shield Veterinarians Who Discuss CBD With Pet Owners
Governor Wes Moore signed SB 54 after unanimous votes in both chambers, barring the state veterinary board from punishing vets who talk to clients about cannabis products for animals.
By CBDWorldNews Editorial Staff | April 23, 2026
Maryland Governor Wes Moore signed SB 54, also known as HB 452, into law on April 14, 2026. The legislation prohibits the Maryland State Board of Veterinary Medical Examiners from taking disciplinary action against licensed veterinarians who discuss the use of cannabis or CBD products with animal owners. Maryland joins California, Nevada, Michigan, and Utah as the fifth state to enact this type of protection. The law takes effect October 1, 2026.
What the Law Does and Does Not Do
SB 54 draws a narrow but important line. It prevents the state veterinary board from revoking, suspending, or otherwise penalizing a veterinarian’s license for discussing cannabis-related products with clients. That includes conversations about CBD oils, hemp-derived supplements, and other cannabis products marketed for animal use.
The law does not require veterinarians to recommend cannabis. It does not create a prescription framework. It does not establish dosing guidelines or product standards. It simply removes the professional risk that has kept many vets from engaging with a topic their clients raise constantly.
Before SB 54, a Maryland veterinarian who told a dog owner about CBD oil for joint support faced a theoretical but real threat. The state board had authority to treat such a conversation as unprofessional conduct. While enforcement actions of that kind were rare nationally, the chilling effect was measurable. Vets stayed quiet, and pet owners turned to the internet for guidance instead.
Unanimous Legislative Support
The bill sailed through both chambers of the Maryland General Assembly without a single opposing vote. The House passed it 137-0. The Senate followed at 45-0. That level of consensus is unusual for any legislation touching cannabis policy, a topic that typically splits lawmakers along party and ideological lines.
The unanimous margins reflect a few factors. The bill’s scope is limited to professional speech protections rather than product legalization. Veterinary associations in the state supported the measure. And legislators from both parties recognized the practical absurdity of punishing a doctor for answering a patient’s owner’s question.
“Nearly 30% of veterinarians report receiving weekly inquiries from pet owners about CBD. This law lets them answer honestly without worrying about their license.”
The bipartisan support also signals that pet CBD occupies a different political space than adult-use cannabis or hemp-derived intoxicants. Lawmakers who might oppose recreational marijuana legalization showed no hesitation about letting veterinarians discuss cannabidiol with a worried dog owner.
The Demand Driving the Legislation
Pet owners are not waiting for regulatory clarity. The pet CBD market reached an estimated $600 million in 2026, and analysts project a 33% compound annual growth rate over the next decade. Retailers specializing in animal wellness products, such as those listed on CBDPet.com, report steady growth in tinctures, chews, and topical products formulated for dogs and cats.
That demand creates an information gap. Pet owners buying CBD products want to talk to their veterinarian about interactions with existing medications, appropriate serving sizes, and product quality. Without legal protection, vets in most states face a difficult choice: give their professional opinion and accept the regulatory risk, or deflect the question and leave their client without qualified guidance.
The states that have already acted show a pattern. California passed its veterinary cannabis discussion law in 2019. Nevada, Michigan, and Utah followed in subsequent years. Each time, the legislation responded to the same dynamic: widespread consumer adoption of pet CBD products outpacing the regulatory framework governing veterinary practice.
For pet owners evaluating product quality, third-party testing databases like SafeCBD.com provide certificate-of-analysis records that veterinarians can now reference in their conversations without professional consequences.
What This Means for Maryland Veterinarians
Starting October 1, 2026, licensed veterinarians in Maryland can discuss cannabis and CBD products with clients during clinical consultations. They can share information about published research. They can address questions about specific products a client has purchased or is considering.
The practical shift will vary by practice. Some veterinarians have quietly discussed CBD with trusted clients for years. Others have maintained a strict policy of avoiding the topic entirely. SB 54 gives the second group permission to engage.
Several professional considerations remain unchanged. Veterinarians still cannot prescribe cannabis, which remains a Schedule I substance under federal law. They still carry professional liability for the advice they give. And they still need to stay current on a rapidly evolving body of research, much of which involves small sample sizes and preliminary findings.
The law also does nothing to regulate the pet CBD products themselves. Quality, potency, and contaminant testing standards remain a patchwork of state rules and voluntary industry practices. A veterinarian protected by SB 54 can discuss CBD freely, but they still lack a standardized framework for evaluating the products their clients bring in.
The Broader Trend
Forty-five states still have no specific protection for veterinarians discussing cannabis with pet owners. In those states, the legal ambiguity persists. Veterinary boards retain the theoretical authority to pursue disciplinary action, even if they rarely exercise it.
Legislative efforts are underway in at least six additional states, according to veterinary advocacy groups tracking the issue. Oregon, Colorado, and New York have seen committee-level activity on similar bills in 2026. The unanimous margins in Maryland may encourage fence-sitting lawmakers elsewhere.
The pet CBD market’s projected growth ensures that client inquiries will only increase. As more pet owners integrate CBD products into their animals’ routines, the pressure on veterinary boards and state legislatures will continue to build. Maryland’s approach, protecting the conversation without endorsing the product, offers a template that other states appear ready to follow.
For now, Maryland veterinarians can mark October 1 on their calendars. After that date, answering a client’s question about CBD will carry professional protection for the first time.
These statements have not been evaluated by the Food and Drug Administration. CBD products are not intended to diagnose, treat, cure, or prevent any disease.
